Xeriant 10-Q: Cash Down to $39,255, Runway ~2 Months, Going Concern Reiterated
XERI sits 88% above its 52-week low of $0.004.
Summary
Xeriant posted a $499,542 quarterly loss, with cash down to $39,255, and said it expects to exhaust available cash in about two months. Post-quarter, it kept funding itself with $0.01-convertible notes and issued 35,000,000 shares for an agreement still being finalized.
Key Events · Earnings and Guidance · XERI
-
Going Concern, ~2-Month Runway
Cash stood at $39,255 at September 30, 2026, down from $87,594 at June 30, and the company expects to expend available cash in approximately two months from November 16, 2026.
-
Quarterly Loss of $499,542
The three months ended September 30, 2026 produced a net loss of $499,542, versus net income of $2,226,072 a year earlier, which included a $2,743,546 gain on extinguishment of debt.
-
Working Capital Deficit Widens
At September 30, 2026 the working capital deficit reached $5,038,605, against total liabilities of $5,077,860 and total assets of $45,754.
-
Post-Quarter Convertible Note Funding
Between October 2 and November 13, 2026, the company issued roughly $625,000 of 10% convertible notes at a $0.01 conversion price, each bundled with warrants at $0.01, including a $250,000 note on October 30 with 25,000,000 warrants.
Analysis · XERI · Manufacturing
The runway has shortened materially: Xeriant ended September 30 with $39,255 of cash and a $5,038,605 working capital deficit, and management now expects to run out of money in about two months from November 16, 2026, versus the ~4 months flagged in the September 28 10-K. The quarter itself lost $499,542, a swing from a year-ago profit that came entirely from a one-time $2,743,546 debt-extinguishment gain. Survival funding is coming from 10% convertible notes convertible at $0.01; the subsequent-events note shows roughly $625,000 of new notes plus tens of millions of warrants issued between October 2 and November 13, alongside 35,000,000 shares issued November 2 for an agreement whose terms are still being finalized. Meanwhile the $3.5M Auctus settlement remains unpaid and has been pushed out again, to December 31, 2026. For existing holders, continued heavy dilution is the base case, and the next capital raise is a near-term necessity rather than an option.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XERI was trading at $0.01 on OTC in the Manufacturing sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.00 to $0.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.